Michael Rosenblatt - Merck Insider

Executive Vice President Chief Medical Officer

Dr. Michael Rosenblatt, M.D., is Executive Vice President, Chief Medical Officer of Merck Co., Inc. He is responsible for the Companys primary voice to the global medical community on critical issues such as patient safety and oversight for the Companys Global Center for Scientific Affairs. Prior to December 2009, Dr. Rosenblatt was the Dean of Tufts University School of Medicine since 2003.
Age: 67  President Since 2009  Ph.D    
908 735-1500  www.merck.com

Management Efficiency

The company has Return on Asset of 0.06 % which means that on every $100 spent on asset it made $0.06 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 6.9 % implying that it generated $6.9 on every 100 dollars invested.
The company has 26.41 B in debt with debt to equity (D/E) ratio of 0.57 which is OK given its current industry classification. Merck Co Inc has Current Ratio of 1.85 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

PRESIDENT Since

Michael McDonnellQuintiles Transnational Holding
2015
Jonathan SeatonIllumina Inc
2017
James ErlingerQuintiles Transnational Holding
2013
Richard LevyIncyte Corporation
2009
Wenqing YaoIncyte Corporation
2014
Paula DowdyIllumina Inc
2016
David HastingsIncyte Corporation
2003
Steven SteinIncyte Corporation
2015
Daniel PlewRegeneron Pharmaceuticals Inc
2016
Mostafa RonaghiIllumina Inc
2008
Kevin KnightlyQuintiles Transnational Holding
2016
Paul BianchiIllumina Inc
2012
Michael AbermanRegeneron Pharmaceuticals Inc
2015
Raymond LowSciClone Pharmaceuticals Inc
2013
Charles DadswellIllumina Inc
2013
Diarmaid CunninghamICON Public Limited Company
2014
Douglas McCorkleRegeneron Pharmaceuticals Inc
2007
Eric SiegelIncyte Corporation
2011
Peter PowchikRegeneron Pharmaceuticals Inc
2006
Derek WinstanlyQuintiles Transnational Holding
2011
Jay MarkowitzRegeneron Pharmaceuticals Inc
2017

Entity Summary

Merck & Co., Inc. offer healthcare solutions worldwide. Merck Co Inc (MRK) is traded on New York Stock Exchange in USA. It is located in NEW JERSEY, U.S.A and employs 66,645 people. Merck is listed under Pharmaceutical Products category by Fama And French industry classification and specializes in Healthcare with concentration in Pharmaceuticals And Biosciences.

Did you try this?

Run Portfolio Optimization Now
   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Hide  View All  Next  Launch Portfolio Optimization
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Merck Co Inc to your portfolio

Top Management

Merck Co Inc Leadership Team
Thomas Glocer, Director
C Kidder, Director
Craig Thompson, Director
Rochelle Lazarus, Director
Michael Rosenblatt, President, Ph.D
Wendell Weeks, Director
Michael Holston, President
Paul Rothman, Director
Adele Ambrose, President
Joseph Romanelli, Executive
Mirian GraddickWeir, President, Ph.D
Peter Wendell, Director
Leslie Brun, Director
Julie Gerberding, President
Pamela Craig, Director, MBA
Patricia Russo, Director
Willie Deese, President
Rita Karachun, SVP
Robert Davis, CFO
Robert Kidder, Director
Thomas Cech, Director, Ph.D
Clark Golestani, EVP
William Harrison, Director
Bruce Kuhlik, EVP
Roger Perlmutter, President, Ph.D
Sanat Chattopadhyay, President
Adam Schechter, President
Carlos Represas, Director
Cuong Do, President
Richard DeLuca, President
Kenneth Frazier, Chairman
Robert JD, CFO
Bridgette Heller, President

Stock Performance

Merck Performance Indicators